Clinical research by Dana-Farber scientists suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could ...

Window of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent ...

Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 ...

Inflammatory bowel diseases (IBDs), which include ulcerative colitis (UC) and Crohn’s disease (CD), are chronic conditions ...

Using a novel deep learning approach, we evaluated the predictive power of the functional connectome during various states (resting state, movie-watching, and n-back) on episodic memory and working ...

Q4 2024 Earnings Call Transcript February 18, 2025 NeoGenomics, Inc. beats earnings expectations. Reported EPS is $0.04, ...

Researchers are launching a multi-site pilot study to assess whether a ketogenic diet, alongside standard medications, can stabilize mood symptoms in young people with bipolar disorder.

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $22.0, along with a high estimate of $25.00 and a low estimate of $14.00. Highlighting a ...

"Once in your life, we should try." Peter Lau's simple seven-word mantra has guided the world's most accomplished racehorse ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...

Background Cancer, a major global health challenge, not only threatens lives but also imposes severe financial burdens, known ...